Table 1. Evaluable Patients Characteristics.
| Characteristics | n |
|---|---|
| Age (y) | |
| Median | 62 |
| Range | 41 - 75 |
| Gender | |
| Male/Female | 25/3 |
| Stage | |
| I | 1 (3.6) |
| IIA | 10 (35.7) |
| III | 12 (42.9) |
| IVA | 4 (14.3) |
| IV B | 1 (3.6) |
| Location | |
| Middle | 5 (17.9) |
| Middle to GE junction | 3 (10.7) |
| Lower | 7 (25.0) |
| GE junction | 13 (46.4) |
| CTV (mL) | |
| Median | 379 mL |
| Range | 157 – 1095 mL |
| Prescription dose (Gy) | |
| Median | 50.4 Gy (or Co-60 GE) |
| Range | 50.4 Gy |
| Radiation type | |
| IMRT/Protons | 18/10 |
| Time between completion of radiotherapy to PET imaging session (days) | |
| Median | 36 days |
| Range | 23 to 53 days |
| Chemotherapy | |
| Induction prior to radiotherapy | 17 (60.7) |
| Concurrent with radiotherapy | 28 (100) |
Abbreviations: GE = Gastro-esophageal, CTV = clinical target volume, Co-60 GE = cobalt-60 Gray Equivalents.
Percentages are presented in parenthesis.